The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

blocks pain signals to the brain, making it nonaddictive. By Gina Kolata The Food and Drug Administration approved a new medication Thursday to treat pain from an injury or surgery. It is ...

The fast-growing nootropics market is set to reach $24.63 billion by 2030. These brain-boosting supplements are becoming more ...

II-73, has the potential to restore memory and cognitive function in a mouse model of Alzheimer's disease. The study demonstrates that the drug improves memory deficits and reverses brain cell damage, ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of ...

The U.S. Food and Drug Administration (FDA) has approved Journavx ... Unlike opioids, which bind to brain receptors to reduce pain but often lead to dependence and addiction, Journavx works ...

The FDA approved Journavx ... for post-surgery pain. The drug, developed by Vertex Pharmaceuticals, blocks pain signals before they reach the brain, avoiding opioid-related addiction risks.

Federal officials on Thursday approved ... brain that receive nerve signals from different parts of the body. Those chemical interactions also give rise to opioids' addictive effects. Vertex’s ...